CD19 CAR T-cells effective with with low dose chemotherapy. - Dr Stephanie Goff
Update: 2016-07-30
Description
Dr Goff speaks with ecancertv at EHA 2016 about her research confirming the efficacy of CD19 chimeric antigen T-cells (CAR T-cells) in patients with advanced lymphoma, even following lower doses of chemotherapy than previously established.
She describes her earlier research in which CD19 CAR T-cells were found to be effective with high dose chemotherapy, and that remission and recovery rates are maintained in this follow-up.
Dr Goff describes neurological side-effects associated with CAR T-cell therapy have been transient, and expects that this balance of chemo-immunotherapy could be brought forwards towards clinical use.
She describes her earlier research in which CD19 CAR T-cells were found to be effective with high dose chemotherapy, and that remission and recovery rates are maintained in this follow-up.
Dr Goff describes neurological side-effects associated with CAR T-cell therapy have been transient, and expects that this balance of chemo-immunotherapy could be brought forwards towards clinical use.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
